The number of Americans with diabetes has grown to nearly 26 million and an estimated one-third of all U.S. adults over 20 now have prediabetes, according to figures released recently by the (CDC).
Prediabetes is a condition in which blood sugar levels are above normal, but not high enough to be declared diabetes. It indicates that the person is at high risk of developing type 2 diabetes, heart disease and stroke.
The findings show an increase from a 2008 CDC report on diabetes. Then, the CDC estimated that 23.6 million Americans had the disease and another 57 million adults had prediabetes.
If the trend continues, the CDC projected that as many as one in three US adults will have diabetes by 2050. One in three!
The vast majority, more than 90 percent of all cases of diabetes are type 2 diabetes, which can be mitigated through lifestyle changes.
The CDC warns the disease is both deadly and costly. Diabetes is the seventh leading cause of death in the US. The disease raises the risk of heart attack, stroke, kidney failure, blindness and amputations. Diabetes costs the U.S. more than $174 billion a year, according to CDC estimates.
There are a number of pharmaceutical approaches to treating diabetes but there is also a large body of well done research demonstrating significant improvements of symptoms using naturally occurring substances. While lifestyle and diet is key to optimal health, natural supplements can aid in significantly improving blood sugar levels. Ortho Molecular Products’s, Diaxinol is a natural and synergistic formula for maintaining balanced blood sugar.
Diaxinol contains five ingredients delivered at targeted potency for maximum efficacy:
Chromium is a critical element in the molecule called glucose tolerance factor (GTF). This is crucial for the glucose uptake into the cells, much like a co factor for insulin. Studies comparing using 1000mcg /day showed a significant improvement in glycosylated hemoglobin, fasting glucose, insulin levels and cholesterol.
Biotin stimulates glucose induced insulin secretion, enhanced insulin sensitivity and the enhancement of glukokinase which accelerates glycolosis in the liver and pancreas. Biotin has been shown to benefit both type I and type II animal models to improve glucose and insulin tolerances. It has been known for many years that biotin deficiency results in impaired utilization of glucose. Blood levels of biotin in patients with NIDDM are lower than in normal controls and lower levels are associated with higher fasting glucose levels. Biotin may act as a cofactor of enzymes required for fatty acid synthesis and may increase the utilization of glucose to synthesize fats.
Vanadyl Sulfate, an oxidative form of vanadium, has been shown to have insulin like properties. One 3 week study at 100mg/day was able to significantly improve hepatic and peripheral muscle sensitivity in NIDDM patients, although it did not show any change in insulin sensitivity in non diabetic people. It was also shown to decrease endogenous glucose production (EGP) by about 20% and this was correlated to a reduction in fasting plasma glucose (FPG). It also correlated with a modest increase in insulin mediated glucose disposal.
Lipoic acid is a unique antioxidant in that in works to recharge the antioxidant properties of vitamin C, which is water soluble, but also to recharge the antioxidant properties of vitamin E, which is fat soluble. It also dramatically increases glutathione levels in the body. Glutathione is an antioxidant that has an affinity for both the eyes and the liver. We chose to source our Lipoic acid from Degussa because their extraction process yields a clean lipoic acid that is free from any solvents or chemicals. Lipoic acid modulates glucose and insulin sensitivities. One study, using oral dosing, showed its ability to increase insulin sensitivity by 27%.
Recently, cinnamon has been touted for its effect on glucose control. We use, Cinnulin, a form of cinnamon that is a 20:1 extract. This compound is water soluble and protects from potentially damaging effects of long term high dose use of a lipid soluble table cinnamon. The cinnulin extract maintains the beneficial type A polymers a that have been shown to have the positive effect on glucose control. Enzyme studies done in vitro show that the bioactive polymers can inhibit PTP-1, a rat homolog of a tyrosine phosphatase (PTP-1B) that inactivate the insulin receptor.
Through enhanced signaling at the cellular level, Diaxinol’s blend of extracts and vitamins support healthy blood glucose levels. Diaxinol’s unique and effective formulation is provided at targeted doses for the best outcome.